Vitamins China Monthly Report

Monthly Reports
Vitamins & Minerals
202410
202409
202408
202407
202406
202405
202404
202403
202402
202401
Free

Vitamins China E-News 202402

Complete
date Published Date:1 Feb 2024
book Table of Contents
toggle
Editor's Note
date Published Date: 22 Jun 2026

China's vitamin market presented a "holiday effect" in Feb. 2024, since Spring Festival holiday was celebrated in this month. Before the holiday, downstream end users already finished stocking up by purchasing vitamins, plus the market inquiry and sales transactions basically stagnated. After the holiday, the transaction atmosphere somewhat rebounded, and the prices of most vitamin varieties remained strong. Market attention on VE and VB12 was rather heightened.


The Department of Food Safety Standards, Risk Surveillance and Assessment of NHC published the drafts of two national food safety standards for public comments, namely National Food Safety Standard—Food Nutritional Fortification Substance Vitamin K2 (Synthesis Method) and National Food Safety Standard—General Rules for the Foods for Special Medical Purpose. The public opinions soliciting ends on 29 Feb., 2024.


As of late Feb., seven listed enterprises that engage in vitamin business released their estimated results for 2023. Amongst the companies expecting financial losses, three reported losses in rather high degrees, including Yifan Pharmaceutical Co., Ltd., Brother Enterprises Holding Co., Ltd. and Hubei Guangji Pharmaceutical Co., Ltd.


News about several projects has been reported, including: Inner Mongolia Baiyi Pharmaceutical Co., Ltd.'s "technical renovation and upgrading project for active pharmaceutical ingredients (API) innovation base"; Guangdong Xinhengjian Biotechnology Co., Ltd.'s "63 t/a new biological medicines and 377.2 t/a nutritional supplements production lines project"; Phase I of Hwatson Biochem's vitamin base project; Inner Mongolia Xingyuan New Material Technology Co., Ltd.'s "800 t/a pharmaceutical and new material intermediates project"; Jiangxi Viablife Biopharmaceutical Co., Ltd.'s "reconstruction and expansion project for amino acid products".


The USD/CNY exchange rate in this Report is USD1.00=CNY7.1049, which was sourced from the People's Bank of China on 1 Feb., 2024. All the prices mentioned in this Report will include the VAT, unless otherwise specified.

toggle
Governmental Direction
date Published Date: 22 Jun 2026
lock
  • NHC publishes drafts of two NFSSs for comments
lock Please purchase to view
toggle
Market Dynamics
date Published Date: 22 Jun 2026
lock
  • Seven listed vitamin firms give estimated results for FY2023
  • Two Chinese firms' recent moves in vitamin nutraceutical field
lock Please purchase to view
toggle
Company Developments
date Published Date: 22 Jun 2026
lock
  • EI report of Baiyi Pharma's upgrading project for APIs published
  • Guangdong Xinhengjian's nutritional supplements project passes energy conservation audit
  • Shengda Bio-pharm discloses latest status of two projects, and expects losses in FY2023
  • Brother Enterprises Holding to end investment agreement for pharmaceutical base
  • Kingdomway's controlled subsidiary to buy out Activ Nutritional, LLC
lock Please purchase to view
toggle
Import and Export Analysis
date Published Date: 22 Jun 2026
lock
  • Imports and exports of selected vitamins in China, Dec. 2023
  • China's vitamin exports in 2023: volume grows and price drops
lock Please purchase to view
toggle
Price Update
date Published Date: 22 Jun 2026
lock
  • Ex-works prices of selected vitamins in China, Feb. 2024
  • China's vitamin market presents "holiday effect" in Feb. 2024
lock Please purchase to view
toggle
News in Brief
date Published Date: 22 Jun 2026
lock
  • Haiwen Biotech launches cosmetic-grade "ND nicotinamide"
  • Hwatson Biochem starts VB1 & VB5 production in vitamin base project (Phase I)
  • Vitamin energy drink "Bull Red" hits market
  • Xingyuan New Material proposes 800 t/a intermediates project
  • EI report of Jiangxi Viablife's reconstruction and expansion project approved
  • Northeast Pharma's scheduled output of APIs for Jan. soars 175% YoY
  • Garden Biopharma reveals new JV plan and 8 new feed additive production licences
  • Heilongjiang NHU's VB12 line passes GMP compliance inspection
  • Update on two of Tianxin Pharma's projects
  • India terminates anti-dumping investigation on Chinese VA palmitate
lock Please purchase to view
Available
Pre-order
202412
202411
202410
202409
202408
202407
Price Details
[Total Product Price] $0
Periodical 202402
$0
Selected Items
1
Total Amount $0
Add to cart